United States
Germany
Japan
United Kingdom
China
Anti-CD20 Reference Antibody (obinutuzumab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
Products
Anti-CD20 Reference Antibody (rituximab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
Anti-CD20 Reference Antibody (Regeneron patent anti-CD20)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-CD20 Reference Antibody (ibritumomab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Mouse |
Anti-CD20 Reference Antibody (divozilimab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
Anti-CD20 Reference Antibody (TRU-015)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Mouse, Cynomolgus |
Anti-CD20 Reference Antibody (ublituximab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-CD20 Reference Antibody (ocrelizumab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
Anti-CD20 Reference Antibody (ripertamab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-CD20 Reference Antibody (ocaratuzumab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-CD20 Reference Antibody (zuberitamab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-CD20 Reference Antibody (veltuzumab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-CD20 Reference Antibody (ofatumumab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
